Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Nano-Based Drug Delivery and Drug Discovery
share announcement

Nano-Based Drug Delivery and Drug Discovery

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Nanomedicine and Nanobiology".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 2459

Special Issue Editor

Dr. Xiangli Shao

E-Mail Website
Guest Editor
Department of Chemistry, The University of Texas at Austin, Austin, TX, USA
Interests: biosensors; functional nucleic acids; nanomaterials; functional DNA nanotechnology

Special Issue Information

Dear Colleagues,

Nanotechnology involves the manipulation and utilization of materials, devices, and systems at the nanometer scale. This rapidly evolving field presents numerous opportunities and a wide array of applications across engineering, medicine, and life sciences. Drug delivery encompasses the various methods by which a drug or active agent is transported to target cells to address health issues or diseases. Nanotechnology shows promise as the preferred platform for drug delivery when addressing the challenges of conventional medications used in the treatment and management of various diseases and developing innovative treatment and diagnostic approaches. By using nanoparticles, drug bioavailability can be enhanced, targeted drug accumulation can be increased, and drug-related side effects can be minimized, ultimately resulting in improved therapeutic outcomes and enhanced patient adherence to treatment protocols.

Potential topics include, but are not limited to, the following:

  • Drug targeting and release (nanoparticles functionalization and optimization, and stimuli-responsive targeting and releasing).
  • Multiple drug administration (multifunctional nanoparticles, combination nanomedicines, personalized nanomedicine, theragnostic nanoparticles, and sequential drug release).
  • Nanocarriers in drug delivery (design and optimization of nanocarriers, and the role of nanocarriers in drug delivery).
  • Smart drug delivery system and its clinical potential.
  • Applications of nano-based systems for drug delivery.

Dr. Xiangli Shao
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology
  • drug discovery
  • drug delivery
  • nanocarriers
  • nanomaterials
  • drug targeting
  • drug release
  • drug therapeutic

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

21 pages, 5723 KiB  
Article
Magnetoelectric Extracellular Vesicle Latency-Targeting (MELT) Nanotherapeutic for the Block-Lock-and-Kill HIV Eradication Strategy
by Mickensone Andre, Nagesh Kolishetti, Adriana Yndart, Arti Vashist, Madhavan Nair and Andrea D. Raymond
Biomedicines 2025, 13(1), 147; https://doi.org/10.3390/biomedicines13010147 - 9 Jan 2025
Viewed by 939
Abstract
Background: Human immunodeficiency virus (HIV) establishes latent infections in cellular reservoirs, including microglia. HC69 cells, a microglial model of HIV latency, contain an HIV promoter long terminal repeat (LTR)-GFP reporter and were used for testing the efficacy of a two-step magnetoelectric nanoparticle (MENP) [...] Read more.
Background: Human immunodeficiency virus (HIV) establishes latent infections in cellular reservoirs, including microglia. HC69 cells, a microglial model of HIV latency, contain an HIV promoter long terminal repeat (LTR)-GFP reporter and were used for testing the efficacy of a two-step magnetoelectric nanoparticle (MENP) and extracellular vesicle (xEV) latency-targeting (MELT) nanotherapeutic. GFP expression in HC69 at rest is low (GFPLo), and upon exposure to LTR, transcription-activating agents (i.e., TNF-α) are induced to be high expressing (GFPHi). Methods: The first step of MELT utilized ZL0580, an HIV Tat inhibitor loaded into EVs (80%) via incubation. ZL0580-EVs were taken up by GFPLo and blocked LTR transcriptional reactivation by 50% and were 90% less toxic than ZL0580 alone. The second step in MELT involved conjugation of monomethyl auristatin E (MMAE) to MENPs. HPLC measurements showed 80% MMAE attachment to MENPs. Flow cytometry-based measurements of the membrane potential indicated that the membranes of GFPHi HC69 were 60% more polarized than GFPLo HC69 cells. More MMAE–MENPs were internalized by GFPLo HC69. Results: Using a mixed-cell blood–brain barrier (BBB) Transwell model, we demonstrated that 20% of MELT crossed the BBB, was taken up by HC69 cells, and reduced LTR reactivation by 10%. Conclusions: Overall, this study demonstrated that MELT can potentially be utilized as a nanotherapeutic to target HIV latency in microglia. Full article
(This article belongs to the Special Issue Nano-Based Drug Delivery and Drug Discovery)
►▼ Show Figures

Figure 1

19 pages, 4683 KiB  
Article
Multifractal Analysis and Experimental Evaluation of MCM-48 Mesoporous Silica as a Drug Delivery System for Metformin Hydrochloride
by Mousa Sha’at, Maria Ignat, Liviu Sacarescu, Adrian Florin Spac, Alexandra Barsan (Bujor), Vlad Ghizdovat, Emanuel Nazaretian, Catalin Dumitras, Maricel Agop, Cristina Marcela Rusu and Lacramioara Ochiuz
Biomedicines 2024, 12(12), 2838; https://doi.org/10.3390/biomedicines12122838 - 13 Dec 2024
Cited by 1 | Viewed by 900
Abstract
Background: This study explored the potential of MCM-48 mesoporous silica matrices as a drug delivery system for metformin hydrochloride, aimed at improving the therapeutic management of type 2 diabetes mellitus. The objectives included the synthesis and characterization of MCM-48, assessment of its [...] Read more.
Background: This study explored the potential of MCM-48 mesoporous silica matrices as a drug delivery system for metformin hydrochloride, aimed at improving the therapeutic management of type 2 diabetes mellitus. The objectives included the synthesis and characterization of MCM-48, assessment of its drug loading capacity, analysis of drug release profiles under simulated physiological conditions, and the development of a multifractal dynamics-based theoretical framework to model and interpret the release kinetics. Methods: MCM-48 was synthesized using a sol–gel method and characterized by SEM-EDX, TEM, and nitrogen adsorption techniques. Drug loading was performed via adsorption at pH 12 using metformin hydrochloride solutions of 1 mg/mL (P-1) and 3 mg/mL (P-2). In vitro dissolution studies were conducted to evaluate the release profiles in simulated gastric and intestinal fluids. A multifractal dynamics model was developed to interpret the release kinetics. Results: SEM-EDX confirmed the uniform distribution of silicon and oxygen, while TEM images revealed a highly ordered cubic mesoporous structure. Nitrogen adsorption analyses showed a high specific surface area of 1325.96 m²/g for unloaded MCM-48, which decreased with drug loading, confirming efficient incorporation of metformin hydrochloride. The loading capacities were 59.788 mg/g (P-1) and 160.978 mg/g (P-2), with efficiencies of 99.65% and 89.43%, respectively. In vitro dissolution studies showed a biphasic release profile: an initial rapid release in gastric conditions followed by sustained release in intestinal fluids, achieving cumulative releases of 92.63% (P-1) and 82.64% (P-2) after 14 hours. The multifractal dynamics-based theoretical release curves closely matched the experimental data. Conclusions: MCM-48 mesoporous silica effectively enhanced metformin delivery, offering a controlled release profile well-suited for type 2 diabetes management. The multifractal theoretical framework provided valuable insights into drug release dynamics, contributing to the advancement of innovative drug delivery systems. Full article
(This article belongs to the Special Issue Nano-Based Drug Delivery and Drug Discovery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop